ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

GSK reorganizes U.K. manufacturing

by Alex Scott
July 24, 2017 | APPEARED IN VOLUME 95, ISSUE 30

GlaxoSmithKline says it will spend more than $160 million to boost the manufacture of respiratory and HIV medicines at its sites in Ware and Barnard Castle, Eng­land, and Montrose, Scotland. Separately, the firm says it may sell off its cephalosporin antibiotics business, including manufacturing assets in Barnard Castle and Ulverston, England, and Verona, Italy. GSK will continue to make other antibiotics such as Augmentin and conduct research on new antibiotics. In another move, the firm plans to sell off its Horlicks drink brand in the U.K. and close its Horlicks production site in Slough, England. GSK is also exploring the sale of other food brands.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment